Literature DB >> 6140590

Can inhibition of hormone secretion be associated with endocrine tumour shrinkage?

M E Kraenzlin, J C Ch'ng, S M Wood, S R Bloom.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6140590     DOI： 10.1016/s0140-6736(83)90847-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Effect of a long-acting somatostatin analogue (octreotide) on circulating tachykinins and the pentagastrin-induced carcinoid flush.

Authors:  H J Balks; J M Conlon; W Creutzfeldt; F Stöckmann
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors.

Authors:  R Arnold; C Neuhaus; R Benning; W B Schwerk; M E Trautmann; K Joseph; C Bruns
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

3.  Inhibitory effect of the somatostatin analog octreotide on rat pituitary tumor cell (GH3) proliferation in vitro.

Authors:  G Pelicci; M C Pagliacci; L Lanfrancone; P G Pelicci; F Grignani; I Nicoletti
Journal:  J Endocrinol Invest       Date:  1990-09       Impact factor: 4.256

4.  Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone.

Authors:  I Torres-Aleman; T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

5.  Somatostatin analogue SMS 201-995 long term therapy for vipoma.

Authors:  L D Juby; D A Burke; A T Axon
Journal:  Postgrad Med J       Date:  1987-04       Impact factor: 2.401
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.